Drugs / rsCD4
rsCD4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00000659 | ? → Jul 1990 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rsCD4 | “A Phase II Trial of rsCD4 and AZT in Patients With AIDS or Advanced AIDS Related Complex (ARC)” NCT00000659 ↗ |
| Known as | rCD4 | “Recombinant soluble CD4 (rCD4) has shown antiretroviral effects and has been shown to be safe when given to AIDS and ARC patients either as a single agent or in combination with AZT.” NCT00000659 ↗ |
| Known as | Recombinant soluble CD4 | “Recombinant soluble CD4 (rCD4) has shown antiretroviral effects and has been shown to be safe when given to AIDS and ARC patients either as a single agent or in combination with AZT.” NCT00000659 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant soluble CD4 (rCD4) has shown antiretroviral effects” NCT00000659 ↗ |